Study: NCT04999761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB154
Description: AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB154
Description: AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.